Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 9985 to 9996 of 19291 entries
Sorted by: Best Match Show Resources per page
Differential regulation of human Eag1 channel expression by serum and epidermal growth factor in lung and breast cancer cells.

OncoTargets and therapy

Acuña-Macías I, Vera E, Vázquez-Sánchez AY, Mendoza-Garrido ME, Camacho J.
PMID: 26527881
Onco Targets Ther. 2015 Oct 16;8:2959-65. doi: 10.2147/OTT.S85504. eCollection 2015.

Oncogenic ether à-go-go-1 (Eag1) potassium channels are overexpressed in most primary human solid tumors. Low oxygen and nutrient/growth factor concentrations play critical roles in tumorigenesis. However, the mechanisms by which tumor cells survive and proliferate under growth factor-depleted conditions...

Cite
Acuña-Macías I, Vera E, Vázquez-Sánchez AY, et al. Differential regulation of human Eag1 channel expression by serum and epidermal growth factor in lung and breast cancer cells. Onco Targets Ther. 2015;8:2959-65doi: 10.2147/OTT.S85504.
Acuña-Macías, I., Vera, E., Vázquez-Sánchez, A. Y., Mendoza-Garrido, M. E., & Camacho, J. (2015). Differential regulation of human Eag1 channel expression by serum and epidermal growth factor in lung and breast cancer cells. OncoTargets and therapy, 82959-65. https://doi.org/10.2147/OTT.S85504
Acuña-Macías, Isabel, et al. "Differential regulation of human Eag1 channel expression by serum and epidermal growth factor in lung and breast cancer cells." OncoTargets and therapy vol. 8 (2015): 2959-65. doi: https://doi.org/10.2147/OTT.S85504
Acuña-Macías I, Vera E, Vázquez-Sánchez AY, Mendoza-Garrido ME, Camacho J. Differential regulation of human Eag1 channel expression by serum and epidermal growth factor in lung and breast cancer cells. Onco Targets Ther. 2015 Oct 16;8:2959-65. doi: 10.2147/OTT.S85504. eCollection 2015. PMID: 26527881; PMCID: PMC4621197.
Copy Download .nbib Format: NLM
Correction: abnormalities in osteoclastogenesis and decreased tumorigenesis in mice deficient for ovarian cancer g protein-coupled receptor 1.

PloS one

Li H, Wang D, Singh LS, Berk M, Tan H, Zhao Z, Steinmetz R, Kirmani K, Wei G, Xu Y.
PMID: 25875929
PLoS One. 2015 Apr 13;10(4):e0125463. doi: 10.1371/journal.pone.0125463. eCollection 2015.

No abstract available.

Cite
Li H, Wang D, Singh LS, et al. Correction: abnormalities in osteoclastogenesis and decreased tumorigenesis in mice deficient for ovarian cancer g protein-coupled receptor 1. PLoS One. 2015;10(4):e0125463doi: 10.1371/journal.pone.0125463.
Li, H., Wang, D., Singh, L. S., Berk, M., Tan, H., Zhao, Z., Steinmetz, R., Kirmani, K., Wei, G., & Xu, Y. (2015). Correction: abnormalities in osteoclastogenesis and decreased tumorigenesis in mice deficient for ovarian cancer g protein-coupled receptor 1. PloS one, 10(4), e0125463. https://doi.org/10.1371/journal.pone.0125463
Li, Hui, et al. "Correction: abnormalities in osteoclastogenesis and decreased tumorigenesis in mice deficient for ovarian cancer g protein-coupled receptor 1." PloS one vol. 10,4 (2015): e0125463. doi: https://doi.org/10.1371/journal.pone.0125463
Li H, Wang D, Singh LS, Berk M, Tan H, Zhao Z, Steinmetz R, Kirmani K, Wei G, Xu Y. Correction: abnormalities in osteoclastogenesis and decreased tumorigenesis in mice deficient for ovarian cancer g protein-coupled receptor 1. PLoS One. 2015 Apr 13;10(4):e0125463. doi: 10.1371/journal.pone.0125463. eCollection 2015. PMID: 25875929; PMCID: PMC4395281.
Copy Download .nbib Format: NLM
[Chromosomal instability in carcinogenesis of cervical cancer.].

Revista medica del Instituto Mexicano del Seguro Social

de Los Santos-Munive V, Alonso-Avelino JA.
PMID: 24290016
Rev Med Inst Mex Seguro Soc. 2013 November-December;51(6):644-649.

In order to spot common chromosomal imbalances in early and late lesions of cervical cancer that might be used as progression biomarkers, we made a search of literature in PubMed from 1996 to 2011. The medical subject headings employed...

Cite
de Los Santos-Munive V, Alonso-Avelino JA. Desequilibrios cromosómicos en el cáncer cervicouterino. [Chromosomal instability in carcinogenesis of cervical cancer.]. Rev Med Inst Mex Seguro Soc. 2013;51(6):644-649
de Los Santos-Munive, V., & Alonso-Avelino, J. A. (2013). Desequilibrios cromosómicos en el cáncer cervicouterino. [Chromosomal instability in carcinogenesis of cervical cancer.]. Revista medica del Instituto Mexicano del Seguro Social, 51(6), 644-649.
de Los Santos-Munive, Victoria, and Alonso-Avelino, Juan Angel. "Desequilibrios cromosómicos en el cáncer cervicouterino." [Chromosomal instability in carcinogenesis of cervical cancer.]. Revista medica del Instituto Mexicano del Seguro Social vol. 51,6 (2013): 644-649.
de Los Santos-Munive V, Alonso-Avelino JA. Desequilibrios cromosómicos en el cáncer cervicouterino. [Chromosomal instability in carcinogenesis of cervical cancer.]. Rev Med Inst Mex Seguro Soc. 2013 November-December;51(6):644-649. Spanish. PMID: 24290016.
Copy Download .nbib Format: NLM
Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells.

Oncogenesis

Hibino S, Saito Y, Muramatsu T, Otani A, Kasai Y, Kimura M, Saito H.
PMID: 24861464
Oncogenesis. 2014 May 26;3:e104. doi: 10.1038/oncsis.2014.17.

Enhancer of zeste homolog 2 (EZH2) enhances tumorigenesis and is commonly overexpressed in several types of cancer. To investigate the anticancer effects of EZH2 inhibitors, microRNA (miRNA) expression profiles were examined in gastric and liver cancer cells treated with...

Cite
Hibino S, Saito Y, Muramatsu T, et al. Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells. Oncogenesis. 2014;3:e104doi: 10.1038/oncsis.2014.17.
Hibino, S., Saito, Y., Muramatsu, T., Otani, A., Kasai, Y., Kimura, M., & Saito, H. (2014). Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells. Oncogenesis, 3e104. https://doi.org/10.1038/oncsis.2014.17
Hibino, S, et al. "Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells." Oncogenesis vol. 3 (2014): e104. doi: https://doi.org/10.1038/oncsis.2014.17
Hibino S, Saito Y, Muramatsu T, Otani A, Kasai Y, Kimura M, Saito H. Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells. Oncogenesis. 2014 May 26;3:e104. doi: 10.1038/oncsis.2014.17. PMID: 24861464; PMCID: PMC4035694.
Copy Download .nbib Format: NLM
Use of ribozymes in validation of targets involved in tumor progression.

Drug discovery today. Technologies

Zaffaroni N, Folini M.
PMID: 24981381
Drug Discov Today Technol. 2004 Oct;1(2):119-24. doi: 10.1016/j.ddtec.2004.07.004.

The discovery over 20 years ago that RNA molecules called ribozymes are able to catalyze chemical reactions was a breakthrough in biology. Because of their high specificity, wide range of target selection and action before protein translation, ribozymes, mainly...

Cite
Zaffaroni N, Folini M. Use of ribozymes in validation of targets involved in tumor progression. Drug Discov Today Technol. 2004;1(2):119-24doi: 10.1016/j.ddtec.2004.07.004.
Zaffaroni, N., & Folini, M. (2004). Use of ribozymes in validation of targets involved in tumor progression. Drug discovery today. Technologies, 1(2), 119-24. https://doi.org/10.1016/j.ddtec.2004.07.004
Zaffaroni, Nadia, and Folini, Marco. "Use of ribozymes in validation of targets involved in tumor progression." Drug discovery today. Technologies vol. 1,2 (2004): 119-24. doi: https://doi.org/10.1016/j.ddtec.2004.07.004
Zaffaroni N, Folini M. Use of ribozymes in validation of targets involved in tumor progression. Drug Discov Today Technol. 2004 Oct;1(2):119-24. doi: 10.1016/j.ddtec.2004.07.004. PMID: 24981381.
Copy Download .nbib Format: NLM
Gene expression of growth signaling pathways is up-regulated in CD133-positive medulloblastoma cells.

Oncology letters

Gu C, Yokota N, Gao Y, Yamamoto J, Tokuyama T, Namba H.
PMID: 22866088
Oncol Lett. 2011 Mar;2(2):357-361. doi: 10.3892/ol.2011.235. Epub 2011 Jan 14.

Medulloblastoma (MB) is the most common malignant brain tumor in children. Cancer initiating cells (CICs) have been proposed to be involved in the development of brain tumors including MB. Prominin-1 antigen (CD133) is a candidate surface molecular marker for...

Cite
Gu C, Yokota N, Gao Y, et al. Gene expression of growth signaling pathways is up-regulated in CD133-positive medulloblastoma cells. Oncol Lett. 2011;2(2):357-361doi: 10.3892/ol.2011.235.
Gu, C., Yokota, N., Gao, Y., Yamamoto, J., Tokuyama, T., & Namba, H. (2011). Gene expression of growth signaling pathways is up-regulated in CD133-positive medulloblastoma cells. Oncology letters, 2(2), 357-361. https://doi.org/10.3892/ol.2011.235
Gu, Chunyu, et al. "Gene expression of growth signaling pathways is up-regulated in CD133-positive medulloblastoma cells." Oncology letters vol. 2,2 (2011): 357-361. doi: https://doi.org/10.3892/ol.2011.235
Gu C, Yokota N, Gao Y, Yamamoto J, Tokuyama T, Namba H. Gene expression of growth signaling pathways is up-regulated in CD133-positive medulloblastoma cells. Oncol Lett. 2011 Mar;2(2):357-361. doi: 10.3892/ol.2011.235. Epub 2011 Jan 14. PMID: 22866088; PMCID: PMC3410605.
Copy Download .nbib Format: NLM
Adenovirus Ad-p53AIP1-mediated gene therapy and its regulation of p53-MDM2 interactions.

Experimental and therapeutic medicine

Jiang Y, Chen H, Jia H, Xu Y, Liu G, Wang Y, Yang X, Lu Y.
PMID: 22993550
Exp Ther Med. 2010 Mar;1(2):363-368. doi: 10.3892/etm_00000057. Epub 2010 Mar 01.

We generated replication-defective adenovirus Ad-p53AIP1 and studied its anti-tumor efficacy both in vitro and in vivo. We demonstrated that Ad-p53AIP1 infection elicited high levels of p53AIP1 expression in cancer cells. We also found that Ad-p53AIP1 expression induced marked apoptosis...

Cite
Jiang Y, Chen H, Jia H, et al. Adenovirus Ad-p53AIP1-mediated gene therapy and its regulation of p53-MDM2 interactions. Exp Ther Med. 2010;1(2):363-368doi: 10.3892/etm_00000057.
Jiang, Y., Chen, H., Jia, H., Xu, Y., Liu, G., Wang, Y., Yang, X., & Lu, Y. (2010). Adenovirus Ad-p53AIP1-mediated gene therapy and its regulation of p53-MDM2 interactions. Experimental and therapeutic medicine, 1(2), 363-368. https://doi.org/10.3892/etm_00000057
Jiang, Yunbo, et al. "Adenovirus Ad-p53AIP1-mediated gene therapy and its regulation of p53-MDM2 interactions." Experimental and therapeutic medicine vol. 1,2 (2010): 363-368. doi: https://doi.org/10.3892/etm_00000057
Jiang Y, Chen H, Jia H, Xu Y, Liu G, Wang Y, Yang X, Lu Y. Adenovirus Ad-p53AIP1-mediated gene therapy and its regulation of p53-MDM2 interactions. Exp Ther Med. 2010 Mar;1(2):363-368. doi: 10.3892/etm_00000057. Epub 2010 Mar 01. PMID: 22993550; PMCID: PMC3445915.
Copy Download .nbib Format: NLM
Dual channel STED nanoscopy of lytic granules on actin filaments in natural killer cells.

Communicative & integrative biology

Mace EM, Orange JS.
PMID: 22808328
Commun Integr Biol. 2012 Mar 01;5(2):184-6. doi: 10.4161/cib.18818.

Natural killer (NK) cells are innate immune effectors that eliminate diseased and tumorigenic targets through the directed secretion of specialized secretory lysosomes, termed lytic granules. This directed secretion is triggered following the formation of an immunological synapse (IS), which...

Cite
Mace EM, Orange JS. Dual channel STED nanoscopy of lytic granules on actin filaments in natural killer cells. Commun Integr Biol. 2012;5(2):184-6doi: 10.4161/cib.18818.
Mace, E. M., & Orange, J. S. (2012). Dual channel STED nanoscopy of lytic granules on actin filaments in natural killer cells. Communicative & integrative biology, 5(2), 184-6. https://doi.org/10.4161/cib.18818
Mace, Emily M, and Orange, Jordan S. "Dual channel STED nanoscopy of lytic granules on actin filaments in natural killer cells." Communicative & integrative biology vol. 5,2 (2012): 184-6. doi: https://doi.org/10.4161/cib.18818
Mace EM, Orange JS. Dual channel STED nanoscopy of lytic granules on actin filaments in natural killer cells. Commun Integr Biol. 2012 Mar 01;5(2):184-6. doi: 10.4161/cib.18818. PMID: 22808328; PMCID: PMC3376059.
Copy Download .nbib Format: NLM
The PML-Interacting Protein DAXX: Histone Loading Gets into the Picture.

Frontiers in oncology

Salomoni P.
PMID: 23760585
Front Oncol. 2013 Jun 07;3:152. doi: 10.3389/fonc.2013.00152. eCollection 2013.

The promyelocytic leukemia (PML) protein has been implicated in regulation of multiple key cellular functions, from transcription to calcium homeostasis. PML pleiotropic role is in part related to its ability to localize to both the nucleus and cytoplasm. In...

Cite
Salomoni P. The PML-Interacting Protein DAXX: Histone Loading Gets into the Picture. Front Oncol. 2013;3:152doi: 10.3389/fonc.2013.00152.
Salomoni, P. (2013). The PML-Interacting Protein DAXX: Histone Loading Gets into the Picture. Frontiers in oncology, 3152. https://doi.org/10.3389/fonc.2013.00152
Salomoni, Paolo. "The PML-Interacting Protein DAXX: Histone Loading Gets into the Picture." Frontiers in oncology vol. 3 (2013): 152. doi: https://doi.org/10.3389/fonc.2013.00152
Salomoni P. The PML-Interacting Protein DAXX: Histone Loading Gets into the Picture. Front Oncol. 2013 Jun 07;3:152. doi: 10.3389/fonc.2013.00152. eCollection 2013. PMID: 23760585; PMCID: PMC3675705.
Copy Download .nbib Format: NLM
Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancer.

Cancers

Oakman C, Pestrin M, Bessi S, Galardi F, Di Leo A.
PMID: 24281114
Cancers (Basel). 2010 Jun 08;2(2):1221-35. doi: 10.3390/cancers2021221.

Adjuvant systemic therapy targets minimal residual disease. Our current clinical approach in the adjuvant setting is to presume, rather than confirm, the presence of minimal residual disease. Based on assessment of the primary tumor, we estimate an individual's recurrence...

Cite
Oakman C, Pestrin M, Bessi S, et al. Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancer. Cancers (Basel). 2010;2(2):1221-35doi: 10.3390/cancers2021221.
Oakman, C., Pestrin, M., Bessi, S., Galardi, F., & Di Leo, A. (2010). Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancer. Cancers, 2(2), 1221-35. https://doi.org/10.3390/cancers2021221
Oakman, Catherine, et al. "Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancer." Cancers vol. 2,2 (2010): 1221-35. doi: https://doi.org/10.3390/cancers2021221
Oakman C, Pestrin M, Bessi S, Galardi F, Di Leo A. Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancer. Cancers (Basel). 2010 Jun 08;2(2):1221-35. doi: 10.3390/cancers2021221. PMID: 24281114; PMCID: PMC3835127.
Copy Download .nbib Format: NLM
Hormonal regulation of zeatin-riboside accumulation by cultured tobacco cells.

Planta

Hansen CE, Meins F, Aebi R.
PMID: 24226072
Planta. 1987 Dec;172(4):520-5. doi: 10.1007/BF00393869.

Auxin (11 μM α-naphthaleneacetic acid) and cytokinin (1.4 μM kinetin) regulate cytokinin accumulation by cytokinin-requiring (C(-)) and cytokinin-autotrophic (C(+)) lines of Havana 425 tobacco (Nicotiana tabacum L.) tissues. No trans-zeatin riboside (ZR) (

Cite
Hansen CE, Meins F, Aebi R. Hormonal regulation of zeatin-riboside accumulation by cultured tobacco cells. Planta. 1987;172(4):520-5doi: 10.1007/BF00393869.
Hansen, C. E., Meins, F., & Aebi, R. (1987). Hormonal regulation of zeatin-riboside accumulation by cultured tobacco cells. Planta, 172(4), 520-5. https://doi.org/10.1007/BF00393869
Hansen, C E, et al. "Hormonal regulation of zeatin-riboside accumulation by cultured tobacco cells." Planta vol. 172,4 (1987): 520-5. doi: https://doi.org/10.1007/BF00393869
Hansen CE, Meins F, Aebi R. Hormonal regulation of zeatin-riboside accumulation by cultured tobacco cells. Planta. 1987 Dec;172(4):520-5. doi: 10.1007/BF00393869. PMID: 24226072.
Copy Download .nbib Format: NLM
Epigenetic therapy in human choriocarcinoma.

Cancers

Takai N, Narahara H.
PMID: 24281181
Cancers (Basel). 2010 Sep 10;2(3):1683-8. doi: 10.3390/cancers2031683.

Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in choriocarcinomas, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. HDAC inhibitors (HDACIs)...

Cite
Takai N, Narahara H. Epigenetic therapy in human choriocarcinoma. Cancers (Basel). 2010;2(3):1683-8doi: 10.3390/cancers2031683.
Takai, N., & Narahara, H. (2010). Epigenetic therapy in human choriocarcinoma. Cancers, 2(3), 1683-8. https://doi.org/10.3390/cancers2031683
Takai, Noriyuki, and Narahara, Hisashi. "Epigenetic therapy in human choriocarcinoma." Cancers vol. 2,3 (2010): 1683-8. doi: https://doi.org/10.3390/cancers2031683
Takai N, Narahara H. Epigenetic therapy in human choriocarcinoma. Cancers (Basel). 2010 Sep 10;2(3):1683-8. doi: 10.3390/cancers2031683. PMID: 24281181; PMCID: PMC3837331.
Copy Download .nbib Format: NLM
Showing 9985 to 9996 of 19291 entries